Drugs / Human normal immunoglobulin G (IgG)
Human normal immunoglobulin G (IgG)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02774239 | Oct 2014 → Oct 2022 | myasthenia gravis | University of Alberta | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human normal immunoglobulin G (IgG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02774239 ↗ |
| Modality | Protein / enzyme biologic | “Human normal immunoglobulin G (IgG)” NCT02774239 ↗ |
| Route | Subcutaneous | “Subcutaneous Immunoglobulin” NCT02774239 ↗ |